In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Instead of Mylan, Teva opts for Allergan's generics business (Actavis Generics), paying $40.5bn, deal value later reduced to $38.8bn

Executive Summary

Months after announcing a hostile bid to buy Mylan NV to create what could have been the second-leading generics company globally, Teva Pharmaceutical Industries Ltd. agreed to acquire Allergan PLC's generic business (Actavis Generics) for $40.5bn--$33.75bn in cash and $6.75bn in Teva stock. Concurrently, Teva officially withdrew its offer for Mylan, which had rejected it anyway. (Mylan is still pursuing its own hostile takeover of Perrigo.)

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies